Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l; glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as solvent for intravenously administered drugs where compatibility has been established.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l; glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as solvent for intravenously administered drugs where compatibility has been established.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 6.24 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established. indications as at 22 august 2005 : compound sodium lactate solution is particularly suitable for replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

inova pharmaceuticals (singapore) pte ltd (incorporated in singapore) malaysia branch - benzydamine hydrochloride -

Сінгапур - англійська - HSA (Health Sciences Authority)

teda pharmaceutical (singapore) pte. ltd. - capsules